Startups

Rock BioMedical, Inc.

Update：2024/07/15

Industries

Biotechnology Biopharma Genetics

Add to Favorites Edit

About

Financials

Patent

News

Main Industry

Biotechnology

Main Product/Service

Rock Bio’s Low-Sugar Universal Vaccine? technology stems from pioneering glycoengineering research led by Professor Chi-Huey Wong and was recognized by IUPAC in 2023 as one of the Top 10 Emerging Technologies in Chemistry. This approach addresses viral immune evasion by removing glycan shields from surface antigens, thereby exposing conserved epitopes and enhancing broad immune responses. The technology has been applied to both protein subunit and mRNA vaccine platforms. RBM001, a glycan-depleted SARS-CoV-2 protein vaccine, has demonstrated protection against major variants and is currently in a Phase 1 clinical trial in the U.S. On the mRNA side, Rock Bio has developed vaccines with modified glycosylation sites that show broad efficacy against SARS-CoV-2, MERS, and SARS-CoV-1, while inducing strong T-cell responses for longer protection. Their RBM-003 influenza vaccine, integrating glycoengineered mRNA with dendritic cell-targeting LNPs, won the inaugural Moderna Taiwan mRNA Innovation Award in 2023. Additionally, Rock Bio’s Glyco-Optimized CHO (GO-CHO) platform enhances therapeutic antibody efficacy by engineering desirable glycan profiles through a dual approach of genetic and medium optimization—offering both improved function and new IP potential for biologics.

Founded Year

2021

Unified Business No.

90255046

Status

Active

Number of Employees

Total Paid-in Capital

1,210,000,000 (NT$)

Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, Ministry of Economic Affairs.

Location of Company

Taiwan , Taipei City

Website

Exclusive content for members

Members-only content. Please log in to access.

Introduction

Rock Bio: Harnessing the power of Glyco-Engineering for disease prevention and treatment Rock Bio is a Glyco-Engineering company dedicated to the development of better vaccines and antibody drugs through manipulation of sugar on the glycoproteins of interest. As one of the most complex and least understood biological processes, glycosylation plays a crucial role in normal physiology and a wide range of disease states, including infectious diseases, cancer, and autoimmune disorders. Over the past few decades, the field of glyco-engineering has been steadily refining its techniques, bridging the gap between scientific exploration and practical application. The progress is positioning the field for major impacts on disease prevention and treatment. At the forefront of this trend, Rock Bio is well poised to take advantage of these developments.
Utilizing our advanced glycoengineering technology and Al-assisted glycosylation design and optimization platform, we precisely modulate glycan structures on key molecules to develop innovative vaccines and antibody therapies. Our low-sugar universal vaccines offer broadly protective immunity, while glyco-optimized biobetters enhance the safety and efficacy of therapeutic antibodies.
Founded in 2021 and built upon a series of glycoengineering technologies through exclusive licensing from Academia Sinica, Rock Bio now has a team of 16 full time employees and four consultants with two sites of operation. Our Taipei site is the headquarter and houses our preclinical R&D. Our clinical development team operates from our Boston site.
Our operation
‧ Rock Bio Taipei- Corporate Headquarter & Preclinical R&D
‧ Rock Bio Boston-Wholly owned subsidiary (Rock Biotherapeutics), Clinical Development

More ↓

Similar Companies

Taiwan Bio-Manufacturing Corporation

TBMC will leverage existing resources to integrate intelligent and smart platform to establish various biopharmaceuticals manufacturing facility.

Biotechnology Biopharma Genetics Manufacturing Pharmaceutical

Rephlmmune Biotechnology Inc.

RephImmune is pioneering a new frontier in cancer immunotherapy with its proprietary platform, Reconstitute-Immunity Antigen-Cell Engager (RACE). This cutting-edge technology is rooted in regeneration biology and is specifically designed to reprogram and rebuild the immune system to effectively target and eliminate solid tumors.

At the core of RACE is a sophisticated algorithmic framework developed by RephImmune, which enables the identification, reassembly, and regeneration of immune components. The platform begins with the selection of 150 promising protein candidates and expands into a vast library of over 500,000 synthetically engineered novel proteins. These proteins are carefully designed and verified for their ability to modulate immune responses and engage tumor-specific antigens.

What sets RephImmune apart is its capacity to reconstitute cellular immunity across 13 different types of immune cells, including various subsets of T cells and innate immune cells. Through this process, the company has developed a novel engineered RACE-T cell specifically designed to attack and destroy solid tumors.

Importantly, the RACE platform is AI-compatible, meaning it can be trained and optimized through machine learning models. This integration of computational biology and artificial intelligence allows for continuous improvement and personalization of immunotherapy strategies, making RephImmune’s approach not only innovative but also scalable and adaptive to future clinical challenges.

Biotechnology Biopharma Genetics Oncology Therapeutics

ARCE THERAPEUTICS, INC.

ARD103
ANTI-CLL1 auto-CAR-T
ARD103, our priority product, is an autologous CAR-T cell manufactured by DashCARR technology with an ultra-fast processing time and stem cell-like phenotypes. ARD103 specifically targeted C-type lectin-like molecule-1 (CLL-1) antigen on both blast cells and leukemia stem cells of acute myeloid leukemia (AML), and was demonstrated to mediate in vitro cytotoxicity, in vivo tumor growth inhibition and ex vivo anti-tumor activity. CLL-1 is highly expressed on both myeloid blasts and leukemia stem cells (LSCs) but is absent on normal hematopoietic stem cells (HSCs), suggesting CLL-1 as an excellent therapeutic target for AML and other potential myeloid malignancies.

The pre-IND meeting consultation with the US FDA was conducted in Q4, 2023, and the following non-clinical studies on CMC and safety evaluation were executed. FDA has cleared ARD103 IND application for a phase 1/2 clinical trial in patients with relapsed/refractory AML and MDS in Oct, 2024. The phase 1/2 clinical trial is an open-label, dose-escalation and expansion study to evaluate the safety and efficacy of ARD103 in r/r AML and MDS patients (NCT06680752).

FDA has granted Orphan Drug Designation (ODD) to ARD103 for AML.